Schizophrenia News and Research

Latest Schizophrenia News and Research

Latest achievements in brain research and treatment for mental disorders

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

30 Aug 2010

23rd ECNP Press conference on impact of circadian rhythms on human brain

All humans are synchronised to the rhythmic light-dark changes that occur on a daily basis. Rhythms in physiological and biochemical processes and behavioural patterns persist in the absence of all external 24-hour signals from the physical environment, with a period that is close to 24 hours

30 Aug 2010

23rd ECNP Congress press conference

The incidence of psychotic disorders varies greatly across places and demographic groups, as do symptoms, course, and treatment response across individuals. High rates of schizophrenia in large cities, and among immigrants, cannabis users, and traumatised individuals reflect the causal influence of environmental exposures. This, in combination with progress in the area of molecular genetics, has generated interest in more complicated models of schizophrenia aetiology that explicitly posit gene-environment interactions.

30 Aug 2010

Researchers examine functions of neuronal diversity

Much like snowflakes, no two neurons are exactly alike. But it's not the size or shape that sets one neuron apart from another, it's the way it responds to incoming stimuli. Carnegie Mellon University researchers have discovered that this diversity is critical to overall brain function and essential in how neurons process complex stimuli and code information.

30 Aug 2010

Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel, investigational antipsychotic agent cariprazine for the treatment of bipolar depression. Cariprazine is currently undergoing Phase III trials for separate indications of schizophrenia and bipolar mania.

30 Aug 2010

An overview of Schizophrenia and psychotic disorders

Schizophrenia and related psychotic disorders are a chronic and often disabling condition. Despite modern treatment techniques they still present an enormous burden to the patients and their relatives and take a serious toll in terms of human suffering and societal expenditure.

30 Aug 2010

Study finds moderate exercise enhances DMN connectivity in specific regions of brain

A group of "professional couch potatoes," as one researcher described them, has proven that even moderate exercise - in this case walking at one's own pace for 40 minutes three times a week - can enhance the connectivity of important brain circuits, combat declines in brain function associated with aging and increase performance on cognitive tasks.

27 Aug 2010

Study on impact of harmful de novo gene mutations on autism, schizophrenia

An international study led by University of Montreal scientists suggests family history may not be a good predictor of the presence of mutations predisposing to autism or schizophrenia. The findings show how new or de novo gene mutations alterations of the cell's DNA play a role in these devastating conditions.

27 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

26 Aug 2010

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

Neuralstem, Inc. announced that it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) to begin a Phase I safety clinical trial for chronic spinal cord injury with its spinal cord stem cells. This multicenter Phase I safety trial will enroll a total of 16 long-term, or chronic, spinal cord injury patients, with an American Spinal Injury Association (ASIA) Grade A level of impairment, one-to-two years post-injury.

26 Aug 2010

SureGene collaborates with Medco Health Solutions to conduct REST study

SureGene, LLC and the Medco Research Institute, LLC, a wholly-owned subsidiary of Medco Health Solutions, Inc., today announced that they have entered into a novel investigative research collaboration to evaluate whether variation in genetic biomarkers previously identified by SureGene can help predict drug response for widely prescribed antipsychotic drugs in patients with serious mental illness.

25 Aug 2010

NARSAD announces 2010 Independent Investigator grants for innovative researchers

NARSAD announced its 2010 Independent Investigator grants totaling in excess of $4.1 million, which will support 42 innovative researchers at the leading edge of discovery within neuroscience and psychiatry. Since 1987 NARSAD has awarded more than $261.6 million in 3,832 grants to 3,132 scientists around the world.

24 Aug 2010

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Neuralstem, Inc. announced that it received notification that the United States Patent and Trademark Office (USPTO) has upheld the patentability, without amendment, of all claims in U.S. Patent No. 5,753,506 and intends to issue a reexamination certificate in due course. This patent describes methods of culturing and expanding neural stem cells.

19 Aug 2010

Deficiencies in DNA loop formation can cause multiple diseases: Research

The genes that are responsible for maintaining each cell type form DNA loops that link control elements for these genes. This surprising genome structure is generated and reinforced by two essential protein complexes that bridge the loops and contribute to proper gene regulation.

19 Aug 2010

Maternal stress contribute to an elevated risk for depression in offspring: Research

For more than a century, clinical investigators have focused on early life as a source of adult psychopathology. Although the hypothesized mechanisms have evolved, a central notion remains: early life is a period of unique sensitivity during which experience confers enduring effects.

19 Aug 2010

Maternal stress associated with increased risk of schizophrenia in male offspring

18 Aug 2010

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

Brain Plasticity Inc., a new technology incubator dedicated to the discovery and development of novel technologies that harness the basic principles of brain plasticity to improve the lives of people with neurological and psychiatric disorders, was recently awarded $3.65 million dollars in two separate grants from the National Institutes of Health (NIH).

18 Aug 2010

Brain stimulation may improve thinking in people with schizophrenia

Mild electrical stimulation to the brain could improve thinking and reduce auditory hallucinations in people with schizophrenia and schizo-affective disorder, researchers from the University of New South Wales (UNSW) have found.

17 Aug 2010

Depressive Cognition Scale questions can detect cognitive symptoms of early depression

A diagnostic test of eight short questions designed by Jaclene Zauszniewski from the Frances Payne Bolton School of Nursing at Case Western Reserve University can be used to detect depressive thinking patterns that lead to clinical depression in women who care for an adult family member with a serious mental illness.

17 Aug 2010

Cortex second-quarter net loss decreases to $0.04 per share

Cortex Pharmaceuticals, Inc. reported a net loss applicable to common stock of approximately $2,454,000, or $0.04 per share, for the quarter ended June 30, 2010, compared with a net loss applicable to common stock of approximately $2,778,000, or $0.06 per share, for the corresponding prior year period.

16 Aug 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

Latest achievements in brain research and treatment for mental disorders

23rd ECNP Press conference on impact of circadian rhythms on human brain

23rd ECNP Congress press conference

Researchers examine functions of neuronal diversity

Forest Laboratories reveals top-line results from cariprazine Phase II clinical trial for bipolar depression

An overview of Schizophrenia and psychotic disorders

Study finds moderate exercise enhances DMN connectivity in specific regions of brain

Study on impact of harmful de novo gene mutations on autism, schizophrenia

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Neuralstem files IND with FDA for spinal cord stem cell Phase I clinical trial for chronic spinal cord injury

SureGene collaborates with Medco Health Solutions to conduct REST study

NARSAD announces 2010 Independent Investigator grants for innovative researchers

USPTO to issue reexamination certificate for Neuralstem's patent for neural stem cell technology

Deficiencies in DNA loop formation can cause multiple diseases: Research

Maternal stress contribute to an elevated risk for depression in offspring: Research

Maternal stress associated with increased risk of schizophrenia in male offspring

NIH awards Brain Plasticity $3.65M to improve cognitive function in people with schizophrenia

Brain stimulation may improve thinking in people with schizophrenia

Depressive Cognition Scale questions can detect cognitive symptoms of early depression

Cortex second-quarter net loss decreases to $0.04 per share

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

Innovation in neuroscience drug discovery - eBook eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in